Phoenix Pharmaceuticals, Inc.

Using our vast experience, we were able to synthesize the human AGRP (83-1321) NH2 peptide. This product proved to be a potent inhibitor of MC3-R and MC4-R function. Another innovation tor Phoenix Pharmaceuticals, as we were first-to-market with ghrelin peptides, antibodies, and immunoassay kits. These were published shortly thereafter in the journal Nature (Kojima et al.). By partnering with 10+ key distributors throughout the globe, we were able to provide our products and services to researchers in over 50 countries. Similar to ghrelin, we were the first to provide synthetic neuronostatin for the research community. This peptide was eventually found to regulate neuronal, cardiovascular, and metabolic functions. Phoenix Europe GmBH, located in Germany, was opened to act as our European headquarters. This would help us connect to researchers in over 20 European countries.